290 related articles for article (PubMed ID: 19818507)
1. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-associated orbitopathy.
Tarabishy AB; Lewis CD; Perry JD
Ophthalmology; 2010 Sep; 117(9):1864; author reply 1864-5. PubMed ID: 20816259
[No Abstract] [Full Text] [Related]
3. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
4. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
5. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
8. [New immunomodulators in treatment of Graves'ophtalmopathy].
Josseaume C; Lorcy Y
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
[TBL] [Abstract][Full Text] [Related]
9. Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells.
McCoy AN; Kim DS; Gillespie EF; Atkins SJ; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1294-9. PubMed ID: 24670080
[TBL] [Abstract][Full Text] [Related]
10. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
[TBL] [Abstract][Full Text] [Related]
12. Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.
Savino G; Mandarà E; Gari M; Battendieri R; Corsello SM; Pontecorvi A
Endocrine; 2015 Feb; 48(1):241-7. PubMed ID: 24880619
[TBL] [Abstract][Full Text] [Related]
13. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
[No Abstract] [Full Text] [Related]
14. Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series.
Savino G; Balia L; Colucci D; Battendieri R; Gari M; Corsello SM; Pontecorvi A; Dickmann A
Minerva Endocrinol; 2013 Jun; 38(2):173-9. PubMed ID: 23732371
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
[TBL] [Abstract][Full Text] [Related]
16. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
Gess AJ; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
[TBL] [Abstract][Full Text] [Related]
17. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
18. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.
Madaschi S; Rossini A; Formenti I; Lampasona V; Marzoli SB; Cammarata G; Politi LS; Martinelli V; Bazzigaluppi E; Scavini M; Bosi E; Lanzi R
Endocr Pract; 2010; 16(4):677-85. PubMed ID: 20350915
[TBL] [Abstract][Full Text] [Related]
19. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Hegedüs L; Smith TJ; Douglas RS; Nielsen CH
Clin Endocrinol (Oxf); 2011 Jan; 74(1):1-8. PubMed ID: 20455896
[TBL] [Abstract][Full Text] [Related]
20. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]